Enzyme replacement therapy for type I gaucher disease

Gaucher Disease

Volumn , Issue , 2006, Pages 341-354

  Zimran, Ari ^a   Bembi, Bruno ^b   Pastores, Gregory M ^c  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951086060     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420005509     Document Type: Chapter

References (53)

1. Barton, N.W. et al. Replacement therapy for inherited enzyme deficiency - macrophage- targeted glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med., 324, 1464, 1991.
2. Grabowski, G.A. et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med., 122, 33, 1995.
3. Desnick, R.J. Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inherit. Metab. Dis., 27, 385, 2004.
4. Zimran, A. et al. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood. 82, 1107, 1993.
5. Perez Calvo, J.I. and Giraldo Castellano P. Home therapy for type 1 Gaucher disease in Spain. Med. Clin.(Barc), 119, 756, 2002.
6. Elstein, D. et al. Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am. J. Obstet. Gynecol., 177, 1509, 1997.
7. Elstein, Y. et al. Pregnancies in Gaucher disease: a 5-year study. Am. J. Obstet. Gynecol. 190, 435, 2004.
8. Rosenberg, M. et al. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood. 93, 2081, 1999.
9. Elstein, D. et al. Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease. Lancet. 351, 1544, 1998.
10. Goitein, O. et al. Lung involvement and enzyme replacement therapy in Gaucher’s disease. QJM. 94, 407, 2001.
11. Mistry, P.K. et al. Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol. Genet. Metab., 77, 91, 2002.
12. Weinreb, N.J. et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin. Hematol., 41 (Suppl. 5), 15, 2004.
13. Elstein, D. et al. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM. 91, 483, 1998.
14. Ashkenazi, A., Zaizov, R., and Matoth, Y. Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. Eur. J. Pediatr., 145, 138, 1986.
15. Gielchinsky, Y. et al. Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease. Br. J. Haematol., 106, 812, 1999.
16. Elstein, D. et al. Gaucher’s disease. Lancet. 358, 324, 2001.
17. Beutler, E. Gaucher Disease: Multiple Lessons from a Single Gene Disease, presented as the Donnall Thomas Lecture at the annual Meeting of the American Society of Hematology, San Diego, Dec. 5-9, 2003.
18. Zimran, A. et al. Low-dose enzyme replacement therapy for Gaucher’s disease: effects of age, sex, genotype, and clinical features on response to treatment. Am. J. Med., 97, 3, 1994.
19. Weinreb, N.J. et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med., 113, 112, 2002.
20. Dawson, A. et al. Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann. Intern. Med., 125, 901, 1996.
21. Pastores, G.M. et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol., 41 (Suppl. 5), 4, 2004.
22. Lester, T.J. et al. Immune thrombocytopenia and Gaucher’s disease. Am. J. Med., 77, 569, 1984.
23. Mistry, P.K. et al. Successful treatment of bone marrow failure in Gaucher’s disease with low-dose modified glucocerebrosidase. QJM. 83, 541, 1992.
24. Gillis, S. et al. Platelet function abnormalities in Gaucher disease patients. Am. J. Hematol., 61, 103, 1999.
25. Zimran, A. et al. Survey of hematological aspects of Gaucher disease. Hematology. 10, 151, 2005.
26. Rosenbloom, B.E. et al. Gaucher disease and cancer incidence: a study from the Gaucher registry. Blood. 105, 4569, 2005.
27. Zimran, A. et al. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol. Dis., 34, 197, 2005.
28. Rodgers, G.P. and Lessin, L.S. Recombinant erythropoietin improves the anemia associated with Gaucher’s disease. Blood. 73, 2228, 1989.
29. Dweck. A. et al. Thrombocytosis associated with enzyme replacement therapy in Gaucher disease. Acta Haematol., 108, 94, 2002.
30. Zimran, A. et al. Correction of neutrophil chemotaxis defect in patients with Gaucher disease by low-dose enzyme replacement therapy. Am. J. Hematol., 43, 69, 1993.
31. Attias, D. and Ruchlemer, R. unpublished, 2005.
32. Rosental, D.I. et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 96, 629, 1995.
33. Poll, L.W. et al. Response of Gaucher bone disease to enzyme replacement therapy. Br. J. Radiol. 75, A25, 2002.
34. Zimran, A., Abrahamov, A., and Elstein, D. Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr. Med. Assoc. J., 2, 80, 2000.
35. Wenstrup, R.J. et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 104, 1253, 2004.
36. Weinreb, N.J., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med., 113, 112, 2002.
37. De Fost, M. et al. Comparison of long term dose-response data using different dosing regimens for a large group of adult type 1 Gaucher disease patients in the Netherlands and Germany, presented at the EWGGD meeting, Barcelona, Sept. 14-17.
38. Vellodi, A, Routine magnetic resonance imaging of the spine in children with Gaucher disease: does it help therapeutic management?, Pediatr. Radiol., 33, 782, 2003.
39. Pastores, G.M. et al. Bone density in Type 1 Gaucher disease. J. Bone Miner. Res., 11, 1801, 1996.
40. Bembi, B. et al. Bone complications in children with Gaucher disease. Br. J. Radiol., 75, A37, 2002.
41. Lebel, U. et al. Bone density changes with enzyme therapy for Gaucher disease. J. Bone Miner. Metab., 22, 597, 2004.
42. Becker-Cohen, R.A. et al. A comprehensive assessment of renal function in patients with Gaucher disease. Am. J. Kidney Dis., 46, 837, 2005.
43. Santoro, D., Rosenbloom, B.E., and Cohen, AH. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy. Am. J. Kidney Dis., 40, E4, 2002.
44. Aerts, J.M. and Hollak, C.E. Plasma and metabolic abnormalities in Gaucher’s disease. Baillieres Clin. Haematol., 10, 691, 1997.
45. Allen, M.J. et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. QJM. 90, 19, 1997.
46. Brautbar, A. et al. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol. Dis., 32, 214, 2004.
47. Zimran, A. et al. Rheological determinants in patients with Gaucher disease and internal inflammation. Am. J. Hematol., 75, 190, 2004.
48. Figueroa, M.L. et al. A less costly regimen of alglucerase to treat Gaucher’s disease. N. Engl. J. Med., 327, 1632, 1992.
49. Pastores, G.M., Sibille, A.R., and Grabowski, G.A. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood. 82, 408, 1993.
50. Anand, G, Uncertain miracle: a biotech drug extends a life, but at what price?, The Wall Street Journal, November 16, 2005; Page A1.
51. Charrow, J. et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J. Pediatr., 144, 114, 2004.
52. Elstein, D. et al. Withdrawal of enzyme replacement therapy in Gaucher’s disease. Br. J. Haematol., 110, 488, 2000.
53. NIH Technology Assessment Panel on Gaucher Disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. JAMA. 27, 548, 1996.